Related Experiment Video
Updated: Nov 10, 2025
Viability Assays for Cells in Culture
Published on: January 20, 2014
Biological Activity of a Thiobarbituric Acid Compound in Neuroblastomas
Sang Y Lee1, Becky Slagle-Webb2, Arun K Sharma3
1Department of Neurosurgery, Pennsylvania State University College of Medicine, Hershey, PA, U.S.A.; lsysys627@gmail.com.
Background/Aim:
We have previously reported the identification of the cytotoxic chemotype compound-I (CC-I) from a chemical library screening against glioblastoma.
Materials And Methods:
The biological activity of CC-I on drug-resistant neuroblastomas [e.g., HFE gene variant C282Y stably transfected human neuroblastoma SH-SY5Y cells (C282Y HFE/SH-SY5Y), SK-N-AS] was characterized using cell culture models and in vivo mouse tumor models.
Results:
CC-I had potent cytotoxicity on therapy-resistant neuroblastoma cells and limited cytotoxicity on human primary dermal fibroblast cells. In addition, CC-I showed a robust anti-tumor effect on therapy-resistant human neuroblastoma C282Y HFE/SH-SY5Y cells but not on SK-N-AS cells in a subcutaneous tumor model. CC-I induced phosphorylation of heat shock protein 27 (HSP27), protein kinase B (Akt), and c-Jun N-terminal kinase (JNK) in C282Y HFE/SH-SY5Y neuroblastoma cells.
Conclusion:
CC-I may be an effective therapeutic option for therapy-resistant neuroblastomas, especially if they express the C282Y HFE gene variant. Its anti-tumor effects are possibly through HSP27-Akt-JNK activation.
Insights
Compound-I (CC-I) effectively targets drug-resistant neuroblastomas, particularly those with the C282Y HFE gene variant. Its anti-tumor effects may involve activating the HSP27-Akt-JNK pathway.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Compound-I (CC-I) was identified as a cytotoxic agent from library screening against glioblastoma.
- Neuroblastomas are aggressive pediatric cancers often developing drug resistance.
Purpose of the Study:
- To characterize the biological activity of CC-I on drug-resistant neuroblastoma cell lines.
- To evaluate the in vivo anti-tumor efficacy of CC-I in preclinical models.
Main Methods:
- Cell culture models of drug-resistant neuroblastomas (C282Y HFE/SH-SY5Y, SK-N-AS) were used.
- In vivo subcutaneous tumor models in mice were employed to assess anti-tumor effects.
- Western blotting was used to analyze protein phosphorylation (HSP27, Akt, JNK).
Main Results:
- CC-I demonstrated potent cytotoxicity against therapy-resistant neuroblastoma cells with limited effects on normal fibroblasts.
- CC-I exhibited significant anti-tumor activity in vivo against C282Y HFE/SH-SY5Y neuroblastoma xenografts.
- CC-I induced phosphorylation of heat shock protein 27 (HSP27), protein kinase B (Akt), and c-Jun N-terminal kinase (JNK) in C282Y HFE/SH-SY5Y cells.
Conclusions:
- CC-I represents a potential therapeutic strategy for therapy-resistant neuroblastomas, especially those harboring the C282Y HFE variant.
- The anti-tumor mechanisms of CC-I may involve the activation of the HSP27-Akt-JNK signaling pathway.
